Rockwell Medical, Inc.
NasdaqCM:RMTI Voorraadrapport
Marktkapitalisatie: US$137.5m
Rockwell Medical Inkomsten in het verleden
Verleden criteriumcontroles 0/6 Rockwell Medical is de winst gegroeid met een gemiddeld jaarlijks percentage van 24.7%, terwijl de Medical Equipment industrie de winst jaarlijks groeide met 13.2%. De inkomsten zijn gegroeid met een gemiddelde van 7.9% per jaar.
Belangrijke informatie
42.1%
Groei van de winst per aandeel
Medical Equipment Groei van de industrie 8.9% Inkomstengroei 7.9% Rendement op eigen vermogen -20.3% Nettomarge -5.2% Volgende winstupdate 12 Nov 2024
Recente prestatie-updates uit het verleden
Rockwell Medical, Inc. to Report Q3, 2024 Results on Nov 11, 2024 Oct 14
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 09
Rockwell Medical, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 12
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind May 15
Rockwell Medical, Inc. to Report Q1, 2024 Results on May 14, 2024 Apr 17
Full year 2023 earnings: EPS exceeds analyst expectations Mar 22
Toon alle updates
Rockwell Medical, Inc. to Report Q3, 2024 Results on Nov 11, 2024 Oct 14
The Market Lifts Rockwell Medical, Inc. (NASDAQ:RMTI) Shares 28% But It Can Do More Sep 29
Rockwell Medical: The Turnaround Is Looking Real Sep 15
New minor risk - Share price stability Sep 04
Rockwell Medical, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates Aug 11
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 09 Rockwell Medical, Inc. Provides Sales Guidance for the Year 2025 and Beyond
Rockwell Medical, Inc. Launches Convenience Pack to Support Home Hemodialysis and Acute Dialysis Facilities Aug 07
Rockwell Medical, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 12
Rockwell Medical, Inc.'s (NASDAQ:RMTI) Subdued P/S Might Signal An Opportunity Jul 12
New major risk - Financial position May 30
Rockwell Medical, Inc. Promotes Tim Chole to Chief Commercial Officer May 30
Consensus EPS estimates fall by 35%, revenue upgraded May 21
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind May 15 Rockwell Medical, Inc. Revises Earnings Guidance for the Year 2024
Does Rockwell Medical (NASDAQ:RMTI) Have A Healthy Balance Sheet? May 08
Rockwell Medical, Inc. to Report Q1, 2024 Results on May 14, 2024 Apr 17
Rockwell Medical, Inc., Annual General Meeting, May 21, 2024 Apr 16
Consensus EPS estimates upgraded to US$0.10 loss, revenue downgraded Mar 28
New minor risk - Share price stability Mar 23
Full year 2023 earnings: EPS exceeds analyst expectations Mar 22
Rockwell Medical, Inc. to Report Q4, 2023 Results on Mar 21, 2024 Feb 09
Is Rockwell Medical (NASDAQ:RMTI) A Risky Investment? Feb 06
Rockwell Medical, Inc. Provides Earnings Guidance for Fourth Quarter and Full-Year 2023 Jan 08
Rockwell Medical, Inc. (NASDAQ:RMTI) Doing What It Can To Lift Shares Dec 25
New major risk - Financial position Nov 19
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 17
Rockwell Medical, Inc. Provides Financial Guidance for the Year 2023 Nov 15 Rockwell Medical, Inc. Appoints Jesse Neri as Senior Vice President, Finance
Rockwell Medical, Inc. Appoints Joan Lau, Ph.D. to the Company's Board of Directors Oct 18
Rockwell Medical, Inc. to Report Q3, 2023 Results on Nov 14, 2023 Oct 17
Is Rockwell Medical (NASDAQ:RMTI) Using Too Much Debt? Oct 11
Forecast to breakeven in 2025 Oct 05
Rockwell Medical, Inc. Announces Resignation of as Senior Vice President, Finance and Chief Accounting Officer Sep 16
Consensus EPS estimates fall by 23% Aug 21 Rockwell Medical, Inc. Revises Financial Guidance for the Year 2023
Second quarter 2023 earnings: EPS misses analyst expectations Aug 14
Consensus estimates of losses per share improve by 15% Jul 18
Rockwell Medical, Inc. to Report Q2, 2023 Results on Aug 14, 2023 Jul 18
Rockwell Medical, Inc. (NasdaqCM:RMTI) agreed to acquire Substantially All Assets of Evoqua Water Technologies LLC for $16 million. Jul 12
New major risk - Share price stability Jul 12
Is Rockwell Medical (NASDAQ:RMTI) Weighed On By Its Debt Load? Jun 02
Consensus estimates of losses per share improve by 13% Jun 01
Rockwell Medical, Inc. Provides Revenue Guidance for Year 2023 May 16
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 16
Full year 2022 earnings: EPS and revenues exceed analyst expectations Mar 31
Rockwell Medical, Inc. to Report Q4, 2022 Results on Mar 30, 2023 Feb 17
Price target decreased to US$5.00 Nov 17
Rockwell Medical, Inc. Provides Earnings Guidance for the Full Year 2022 Nov 15
Is There Now An Opportunity In Rockwell Medical, Inc. (NASDAQ:RMTI)? Oct 25
Rockwell Medical, Inc. to Report Q3, 2022 Results on Nov 14, 2022 Oct 18
Rockwell Medical, Inc. Names Heather Hunter as SVP, Chief Corporate Affairs Officer Sep 08
An Intrinsic Calculation For Rockwell Medical, Inc. (NASDAQ:RMTI) Suggests It's 46% Undervalued Sep 02
Consensus estimates of losses per share improve by 24% Aug 22
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 16
Rockwell Medical Q2 Earnings Preview Aug 12
Rockwell Medical, Inc. to Report Q2, 2022 Results on Aug 15, 2022 Aug 04
Price target decreased to US$19.00 Jul 01 Rockwell Medical, Inc. Provides Clinical Update Rockwell Medical, Inc. announced that it has received $14.9 million in funding Jun 04
Rockwell Medical Regains Compliance with Nasdaq Listing Requirements Jun 02
Rockwell Medical, Inc. Submits Supplemental Data to FDA for IND Application for Phase 2 FPC Home Infusion Trial May 13
Rockwell Medical, Inc. to Report Q1, 2022 Results on May 16, 2022 May 12
Rockwell Medical, Inc. Announces Completion of Patient Enrollment Ahead of Schedule in Pivotal Phase 3 Clinical Trial of Triferic(R) in China Apr 26 Rockwell Medical, Inc. announced delayed annual 10-K filing Apr 03
Rockwell Medical: Triferic Remains Key Despite Sluggish Growth Profile Mar 02
Forecast to breakeven in 2023 Feb 16
Price target decreased to US$4.00 Jan 19
Rockwell Medical Receives Important Feedback from FDA on Its IND Application for Phase 2 Trial of Ferric Pyrophosphate Citrate in Home Infusion Dec 15
Third quarter 2021 earnings released: US$0.081 loss per share (vs US$0.10 loss in 3Q 2020) Nov 17
Rockwell Medical: Down But By No Means Out Oct 05
Second quarter 2021 earnings released: US$0.09 loss per share (vs US$0.099 loss in 2Q 2020) Aug 18
Rockwell Medical Receives Written Notice from the Nasdaq Stock Market Jun 19
Rockwell Medical pops 6% on licensing deal for Triferic AVNU in Turkey Jun 08
First quarter 2021 earnings released: US$0.083 loss per share (vs US$0.12 loss in 1Q 2020) May 19
Rockwell Medical, Inc. Announces Marketing Approval of Triferic® AVNU™ in Canada Apr 29
Rockwell Medical, Inc. to Report Q4, 2020 Results on Mar 31, 2021 Mar 19
Health Check: How Prudently Does Rockwell Medical (NASDAQ:RMTI) Use Debt? Mar 08
Rockwell Medical Announces U.S. Availability of Triferic AVNU for Replacement of Iron and Maintenance of Hemoglobin in Patients on Hemodialysis Feb 10
Some Rockwell Medical, Inc. (NASDAQ:RMTI) Analysts Just Made A Major Cut To Next Year's Estimates Feb 10
New 90-day high: US$1.48 Feb 09
Rockwell Medical, Inc.(NasdaqGM:RMTI) dropped from S&P Healthcare Equipment Select Industry Index Jan 28
Rockwell Medical, Inc. Announces Termination of Ajay Gupta, M.D. as the Company’s Chief Scientific Officer Jan 26
Hoe Rockwell Medical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis NasdaqCM:RMTI Opbrengsten, kosten en inkomsten (USD Millions ) Datum Inkomsten Inkomsten G+A Uitgaven R&D-uitgaven 30 Jun 24 94 -5 15 1 31 Mar 24 87 -9 15 1 31 Dec 23 84 -9 14 1 30 Sep 23 81 -9 15 1 30 Jun 23 76 -12 16 1 31 Mar 23 76 -13 17 2 31 Dec 22 73 -19 18 3 30 Sep 22 69 -25 18 4 30 Jun 22 66 -29 20 5 31 Mar 22 63 -32 20 7 31 Dec 21 62 -33 21 7 30 Sep 21 62 -32 23 7 30 Jun 21 61 -32 23 8 31 Mar 21 62 -31 22 7 31 Dec 20 62 -31 24 7 30 Sep 20 63 -30 24 7 30 Jun 20 63 -30 25 7 31 Mar 20 62 -33 28 8 31 Dec 19 61 -34 30 7 30 Sep 19 63 -36 31 7 30 Jun 19 64 -33 31 6 31 Mar 19 64 -35 29 4 31 Dec 18 63 -32 23 6 30 Sep 18 61 -32 21 6 30 Jun 18 59 -32 20 7 31 Mar 18 58 -27 21 7 31 Dec 17 57 -26 23 6 30 Sep 17 56 -22 23 5 30 Jun 17 54 -21 24 5 31 Mar 17 54 -20 22 6 31 Dec 16 53 -20 21 6 30 Sep 16 54 -21 21 7 30 Jun 16 56 -18 20 7 31 Mar 16 55 -16 19 5 31 Dec 15 55 -14 19 5 30 Sep 15 56 -15 19 5 30 Jun 15 55 -17 19 5 31 Mar 15 55 -17 20 4 31 Dec 14 54 -21 18 8 30 Sep 14 54 -23 16 12 30 Jun 14 53 -33 16 21 31 Mar 14 53 -41 15 31 31 Dec 13 52 -49 14 39
Kwaliteitswinsten: RMTI is momenteel verliesgevend.
Groeiende winstmarge: RMTI is momenteel verliesgevend.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: RMTI is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 24.7% per jaar verminderd.
Versnelling van de groei: Het is niet mogelijk om de winstgroei van RMTI over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.
Winst versus industrie: RMTI is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Medical Equipment industrie ( 11.7% ).
Rendement op eigen vermogen
Hoge ROE: RMTI heeft een negatief Return on Equity ( -20.31% ), omdat het momenteel verliesgevend is.
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
